摘要
Abstract
Objective:To investigate the clinical value of Acyclovir combined with atomized inhalation of Recombinant Human Interferon α2b in the treatment of children with infectious mononucleosis.Method:A total of 78 children with infectious mononucleosis admitted to Yichun People's Hospital from September 2021 to September 2022 were selected as the research objects,and were divided into groups according to their treatment time,the children who were treated from September 2021 to February 2022 were enrolled as the reference group(39 cases)and were treated with Acyclovir alone;the children who were treated from March to September 2022 were enrolled as the study group(39 cases)and were treated with Recombinant Human Interferon α2b on the basis of the reference group.The treatment efficiency,clinical symptoms regression time,C reactive protein,procalcitonin levels and adverse reactions were compared between the two groups.Result:The total effective rate of the study group was higher than that of the reference group,and the fever subsidence time,lymph node shrinkage time,liver and spleen retraction time and kinase recovery time of the study group were shorter than those of the reference group,the differences were statistically significant(P<0.05).After treatment,the levels of C reactive protein and procalcitonin in the study group were lower than those in the reference group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the study group was lower than that in the reference group,but there was no statistically significant difference between the two groups(P>0.05).Conclusion:For children with infectious mononucleosis,the active treatment of Acyclovir combined with atomized inhalation of Recombinant Human Interferon α2b can achieve a more ideal therapeutic effect,improve clinical symptoms and levels of C reactive protein and procalcitonin,with good drug safety.关键词
传染性单核细胞增多症/重组人干扰素α2b/阿昔洛韦/C反应蛋白/降钙素原Key words
Infectious mononucleosis/Recombinant Human Interferon α2b/Acyclovir/C reactive protein/Procalcitonin
